Nintedanib Eugia

Nintedanib, the active ingredient in Nintedanib Eugia, is a tyrosine kinase inhibitor presented as an oral formulation for systemic use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain non‑small cell lung cancers.

GNH USA supplies Nintedanib Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with distribution networks spanning Europe, Asia and the Americas, and adhering to stringent quality standards.

Nintedanib is used in fibrotic lung diseases and selected oncology settings, targeting pathways that drive fibroblast activity and tumor angiogenesis. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary outcomes and stabilizes fibrosis. - Non‑small cell lung cancer: inhibits tumor growth and angiogenesis as part of combination therapy.

Nintedanib may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may affect appetite. - Vomiting: occasional episodes, usually self‑limited. - Abdominal pain: discomfort in the stomach region. - Elevated liver enzymes: mild increases in ALT/AST. - Decreased appetite: reduced desire to eat. Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Cardiovascular events: arterial thromboembolism or myocardial infarction. - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Interstitial lung disease exacerbation: worsening respiratory symptoms.

When prescribing Nintedanib, clinicians should consider several safety and handling measures. - Liver function monitoring: check ALT, AST and bilirubin before starting and periodically during therapy. - Gastrointestinal management: advise patients to stay hydrated and report severe diarrhea. - Cardiovascular risk assessment: evaluate history of arterial thrombotic events prior to use. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Nintedanib can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure and toxicity. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding. - Dual antiplatelet therapy: additive bleeding risk. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug levels, decreasing effectiveness. - P‑glycoprotein inhibitors (e.g., verapamil): modest increase in exposure. - NSAIDs or aspirin: monitor for gastrointestinal bleeding.